EUROPEAN COMMISSION EXPANDS INDICATION FOR PLAVIX (CLOPIDOGREL BISULFATE) OFFERING NEW OPTION FOR PATIENTS WITH MOST SEVERE TYPE OF HEART ATTACK

Sanofi-aventis and Bristol-Myers Squibb Company announced that the European Commission has granted a new indication for the antiplatelet agent PLAVIX (clopidogrel bisulfate) to include patients with ST-segment Elevation acute Myocardial Infarction (STEMI) who are eligible for thrombolytic therapy. Yahoo Finance (http://biz.yahoo.com/cnw/060907/e_sanofi_a_plavix_r.html?.v=1)